PhuturdexDrug Pipeline Intelligence

Phuturdex › Diseases › Inborn metabolic brain disease

Drugs in development · updated 30 October 2026

Inborn metabolic brain disease: drugs in development

As of 30 October 2026 there are 3 active clinical trials (recruiting or ongoing, phases I–III) on 3 drugs for inborn metabolic brain disease. 3 are experimental, that is not yet approved in the United States.

3Active trials
3Experimental drugs
1Experimental, in phase III

Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.

Sign in free →

Experimental drugs

Not yet approved by the US FDA for any indication.

DrugMost advanced phaseActive trialsReference trial
ECUR-506III1NCT06255782
FBX-101I–II1NCT05739643
DUOC-01I1NCT02254863

Sorted by most advanced phase and number of active trials.

All 3 drugs, with the details

In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.

Open in Phuturdex →

Specific forms

Broader categories

Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: Wikidata; NLM MeSH term: D020739 “Brain Diseases, Metabolic, Inborn”.

ItalianoFrançaisDeutsch